A recent preliminary review conducted by the U.S. Food and Drug Administration (FDA) has found no evidence linking popular drugs used to treat diabetes and obesity with an increased risk of suicidal thoughts or actions. While the review is encouraging, the FDA acknowledges that there may still be a small risk, and they will continue to investigate the matter.
The FDA reviewed the safety profiles of over a dozen drugs, including Ozempic, Wegovy, and Mounjaro. They based their findings on reports from patients who have been using these medications. The agency emphasized the importance of patients reporting any concerns or side effects to their healthcare providers.
This examination comes on the heels of a federally funded study that revealed people taking semaglutide, the active ingredient in Ozempic and Wegovy, had a lower risk of experiencing suicidal thoughts compared to individuals using different medications to manage obesity and diabetes. The investigation was prompted by anecdotal reports from European regulators that suggested a potential link between semaglutide and self-harming thoughts.
However, the FDA's initial assessment did not find any substantial evidence supporting claims that these medications cause suicidal thoughts or actions. GLP-1 receptor agonists, a class of drugs approved since 2005, including the ones mentioned above, are known to help manage blood sugar levels and reduce the risk of heart disease in people with type 2 diabetes. Some of these drugs also aid in weight loss for those struggling with obesity or being overweight.
Monitoring the safety and efficacy of drugs is an ongoing process. The FDA remains committed to carefully examining all available data, including patient reports, to ensure the continued well-being of individuals who rely on these medications. Patients who have concerns or experience any adverse effects are urged to discuss them with their healthcare providers promptly.
It is important to note that the review conducted by the FDA is preliminary, and further investigations might be required to provide a comprehensive understanding of the potential side effects associated with these medications. Patient safety is paramount, and regulators will continue to closely monitor and evaluate any potential risks that may arise.
